Infectious Complications of Tumor-Infiltrating Lymphocyte (TIL) Therapy for Metastatic Melanoma
Open Forum Infectious Diseases · 2026-11-12
DOI: 10.1093/ofid/ofag732 ↗Abstract
Abstract Background Tumor-infiltrating lymphocyte (TIL) therapy is a novel cellular immunotherapy approved for the treatment of metastatic melanoma. The infectious complications of TIL therapy are poorly understood. We aimed to describe the infections that occurred and the yield of diagnostic studies in patients who underwent TIL therapy at our institution. Methods We conducted a retrospective cohort study of patients who received TIL therapy at Stanford Healthcare between April 2024 and June 2025. Patient charts were reviewed to extract information on demographics as well as laboratory and clinical findings. Each case was reviewed to determine the presence or absence of infections. Results Thirty patients underwent TIL therapy during the study period. All patients developed neutropenia, of which 25 developed fevers. Investigations for causes of fever were rarely positive (including 0/149 blood cultures and 0/88 tests for fungal infections). False-positive results were more common than true positives. Patients received a median of 10 days of antipseudomonal antibiotics and frequently also received gram-positive coverage (n=11/25) and antifungal coverage (n=13/25). Six patients had documented infections, including intra-abdominal infections in 4 cases, possible superinfected tumor in 1 case, and CMV viremia with CMV colitis in 1 case. One patient developed Clostridioides difficile colitis following their receipt of systemic antibiotics. Conclusion Fever is common in patients undergoing TIL treatments, but most patients do not have documented infection. Extensive investigations rarely yield positive results. Opportunistic infections are uncommon but can occur, and clinicians should remain vigilant for this possibility, while carefully weighing the risks and benefits of specialized testing and empiric treatments.
EUVIMED